The emerging treatment landscape of targeted therapy in non-small-cell lung cancer

被引：487
|
作者：
Yuan, Min [1 ,2 ]
Huang, Li-Li [1 ,2 ]
Chen, Jian-Hua [1 ,3 ]
Wu, Jie [3 ,4 ]
Xu, Qing [1 ,2 ]
机构：
[1] Tongji Univ, Dermatol Hosp, Dept Oncol, Sch Med, Shanghai 200443, Peoples R China
[2] Tongji Univ, Shanghai Peoples Hosp 10, Dept Oncol, Sch Med, Shanghai 200072, Peoples R China
[3] Univ Oklahoma, Hlth Sci Ctr, Peggy & Charles Stephenson Canc Ctr, Oklahoma City, OK 73104 USA
[4] Univ Oklahoma, Hlth Sci Ctr, Dept Pathol, Oklahoma City, OK USA
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2019年 / 4卷 / 1期
基金：
中国国家自然科学基金;
关键词：
EPIDERMAL-GROWTH-FACTOR; TYROSINE KINASE INHIBITORS; ANTI-HER3; MONOCLONAL-ANTIBODY; NIVOLUMAB PLUS IPILIMUMAB; RECEPTOR GENE-MUTATIONS; RANDOMIZED PHASE-III; OPEN-LABEL; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; EGFR MUTATIONS;
D O I：
10.1038/s41392-019-0099-9
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
Lung cancer is one of the most common cancer in the world. In 2018, there were over 2 million new cases of lung cancer and over 1.7 million deaths were attributed to lung cancer. Targeted therapy has emerged as an important mean of the disease management for patients with non-small-cell lung cancer (NSCLC). Herein, we review and analyze recent literature, discuss the targeting pathways and ongoing clinical trials in lung cancer. Chemotherapy is no longer the best available treatment for all patients. Therapeutic decisions should be guided by an understanding of the molecular features of patient's tumor tissues. The future gains will likely emerge from finding optimal ways of combining targeted therapy, immunotherapy, and chemotherapy.
引用
收藏
页数：14
相关论文
共 50 条
  • [41] Radiation Therapy in Non-Small-Cell Lung Cancer
    Dohopolski, Michael
    Gottumukkala, Sujana
    Gomez, Daniel
    Iyengar, Puneeth
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2021, 11 (10):
  • [42] Molecular Pathogenesis, Organ Metastasis, and Targeted Therapy for Non-Small-Cell Lung Cancer
    Abdullah, Salik
    Chakraborty, Ratul
    Kumkar, Pratiksha Somnath
    Debnath, Biplab
    Bala, Asis
    JOURNAL OF ENVIRONMENTAL PATHOLOGY TOXICOLOGY AND ONCOLOGY, 2024, 43 (03) : 13 - 38
  • [43] Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin
    Oser, Matthew G.
    Niederst, Matthew J.
    Sequist, Lecia V.
    Engelman, Jeffrey A.
    LANCET ONCOLOGY, 2015, 16 (04) : E165 - E172
  • [44] The landscape of EGFR pathways and personalized management of non-small-cell lung cancer
    Cheng, Liang
    Zhang, Shaobo
    Alexander, Riley
    Yao, Yongxue
    MacLennan, Gregory T.
    Pan, Chong-xian
    Huang, Jiaoti
    Wang, Mingsheng
    Montironi, Rodolfo
    Lopez-Beltran, Antonio
    FUTURE ONCOLOGY, 2011, 7 (04) : 519 - 541
  • [45] Role of gefitinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
    Li, Meng-Jiao
    He, Qing
    Li, Mei
    Luo, Feng
    Guan, Yong-Song
    ONCOTARGETS AND THERAPY, 2016, 9 : 1291 - 1302
  • [46] Role of erlotinib in the targeted treatment of non-small-cell lung cancer in Chinese patients
    Li, Wei
    Zhou, Fei
    Zhou, Caicun
    ONCOTARGETS AND THERAPY, 2014, 7 : 253 - 261
  • [47] Molecularly Targeted Therapies in Locally Advanced Non-Small-Cell Lung Cancer
    Devarakonda, Siddhartha
    Morgensztern, Daniel
    Govindan, Ramaswamy
    CLINICAL LUNG CANCER, 2013, 14 (05) : 467 - 472
  • [48] Drug resistance to molecular targeted therapy and its consequences for treatment decisions in non-small-cell lung cancer
    Spaans, Johanna N.
    Goss, Glenwood D.
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [49] Incorporation of Antiangiogenic Therapy Into the Non-Small-Cell Lung Cancer Paradigm
    Chu, Benjamin F.
    Otterson, Gregory A.
    CLINICAL LUNG CANCER, 2016, 17 (06) : 493 - 506
  • [50] Non-small cell lung cancer: an update on emerging EGFR-targeted therapies
    Favorito, Valentina
    Ricciotti, Ilaria
    De Giglio, Andrea
    Fabbri, Laura
    Seminerio, Renata
    Di Federico, Alessandro
    Gariazzo, Eleonora
    Costabile, Silvia
    Metro, Giulio
    EXPERT OPINION ON EMERGING DRUGS, 2024, 29 (02) : 139 - 154
12345